Rationale: Pre-exposure prophylaxis is a strategy that aims to use antiretrovirals to reduce the risk of HIV infection. Studies in non-human primates have shown that both oral and topical applications of ARVs before exposure reduce risk or completely prevent infection with challenge by an HIV-like virus that causes disease in monkeys.
TDF/FTC (marketed under the name Truvada) is an antiretroviral used by HIV-positive people as part of highly active antiretroviral therapy.
Study question(s): This study is examining the safety and efficacy of two different pre-exposure prophylaxis strategies (once-daily TDF/FTC and once-daily TDF) in reducing the risk of HIV transmission within HIV-serodiscordant couples.
Participants: 4,700 HIV-serodiscordant couples
Countries: Kenya, Uganda
Trial sponsors and collaborators: Bill & Melinda Gates Foundation, Gilead Sciences, University of Washington
When can we expect results? Initial results in July 2011, additional data in 2012 or 2013.
To learn more visit:
http://clinicaltrials.gov/ct2/show/study/NCT00557245?term=PartnersPrEP&rank=1
http://depts.washington.edu/uwicrc/research/studies/PrEP.html